Table 1.
Treg-targeting antibody drugs approved by FDA or in clinical investigation.
| Target | Drug name | IgG Type blocking/depletion/agonist |
Cancer type | Company | Year of approved/clinical phase |
|---|---|---|---|---|---|
| CTLA4 | Ipilimumab | IgG1 blocking/depletion |
Liver, non-small-cell lung cancer, mesothelioma, renal cell carcinoma | Bristol-Myers Squibb | 2011 |
| Tremelimumab, combination with durvalumab (anti-PD-L1) |
IgG2 blocking | Hepatocellular carcinoma | AstraZeneca | 2022 | |
| TIGIT | Tiragolumab | IgG1 blocking | Breast, cervical, esophageal, gastric, liver, lung, rectal cancer | Roche | Phase 2/3 NCT04300647 |
| Ociperlimab | IgG1 blocking | Cervical, lung, squamous cell cancer | Beigene | Phase 2 NCT04693234 | |
| Vibostolimab | IgG1 blocking | Triple negative breast, colorectal, endometrial, esophageal, gastrointestinal, stomach, haematological, head and neck, lung, ovarian, prostate, hepatocellular carcinoma, malignant melanoma |
Merck Sharp Dohme | Phase 2 NCT04305041 |
|
| Domvanalimab | IgG1 blocking | Glioblastoma, non-small-cell lung cancer | Arcus Biosciences | Phase 2 NCT05130177 |
|
| GITR | BMS986156 | IgG1 agonist | Liver, lung cancer | Bristol-Myers Squibb | Phase 1/2 NCT02598960 |
| Ragifilimab | IgG1 agonist | Glioblastoma, head and neck cancer | Agenus | Phase 2 NCT04225039 |
|
| REGN-6569 | – agonist |
Advanced solid tumor, head and neck tumor, squamous cell carcinoma | Regeneron Pharmaceuticals | Phase 1 NCT04465487 |
|
| MK-4166 | IgG1 agonist | Advanced solid tumor | Merck Sharp Dohme | Phase 1 NCT02132754 |
|
| GWN-323 | IgG1 agonist | Advanced solid tumor, lymphoma | Novartis | Phase 1 NCT02740270 |
|
| OX40 | BMS986178 | IgG1 agonist | B-cell lymphoma | Bristol-Myers Squibb | Phase 1/2 NCT02737475 |
| GSK3174998 | IgG1 agonist | Head and neck cancer, multiple myeloma | GlaxoSmithKline | Phase 1/2 NCT04126200 | |
| INCAGN1949 | IgG1 agonist | Unspecified solid cancer | Agenus | Phase 1/2 NCT02923349 | |
| Ivuxolimab | IgG2 agonist | Breast cancer, acute myelogenous leukemia, squamous cell, renal cell carcinoma |
Pfizer | Phase 2 NCT03971409 | |
| CD27 | Varlilumab | IgG1 agonist | Glioblastoma, haematological lymphoma, prostate cancer, malignant melanoma, renal cell carcinoma | Celldex Therapeutics | Phase 2 NCT04941287 |
| GEN-1053 | – agonist |
Solid tumor | Genmab | Phase 1/2 NCT05435339 | |
| Boserolimab | – agonist |
Advanced solid tumor, lung cancer | Merck Sharp Dohme | Phase 2 NCT04165096 | |
| TNFR2 | BI-1808 | IgG1 blocking | Lymphoma, cutaneous T-cell cancer | BioInvent | Phase 1/2 NCT04752826 |
| LBL019 | – – |
Unspecified solid cancer | Nanjing Leads Biolabs | Phase 1/2 NCT05223231 | |
| CD25 | Camidanlumab tesirine | IgG1 ADC depletion |
Leukemia, advanced solid tumor, burkitts lymphoma, colon tumor, cutaneous T-cell lymphoma, follicle center lymphoma | ADC Therapeutics | Phase 2 NCT04052997 |
| RG-6292 | – depletion |
Advanced solid tumor | Roche | Phase 1 NCT04158583 | |
| RM-1995 | – ADC depletion |
Head and neck tumor, Squamous cell carcinoma | Rakuten Medical | Phase 1 NCT05220748 | |
| CCR4 | Mogamulizumab | IgG1 depletion | Adult T-cell lymphoma, cutaneous T-cell lymphoma, peripheral T-cell lymphoma, sezary syndrome | Kyowa Kirin | 2018 |
| CCR8 | BMS-986340 | – depletion |
Metastatic colorectal, esophageal, head and neck, stomach, non-small-cell lung cancer | Bristol-Myers Squibb | Phase 1/2 NCT04895709 |
| GS-1811 | – depletion |
Advanced solid tumor | Gilead Sciences | Phase 1 NCT05007782 | |
| S-531011 | IgG1 depletion | Adenocarcinoma, breast, Head and neck cancer, renal cell carcinoma, squamous cell carcinoma | Shionogi & Co | Phase 1/2 NCT05101070 | |
| LM-108 | – depletion |
Advanced solid tumor | LaNova Medicines | Phase 1/2 NCT05199753 | |
| BAY-3375968 | IgG1 depletion | Breast, head and neck, non-small-cell lung cancer, squamous cell carcinoma, melanoma | Bayer | Phase 1 NCT05537740 |